APPROVED_Xeomin_Prescribing_information_UKIE_combined_June_2019_v4 – Supplemental material for The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)

Morgante, Francesca; Bavikatte, Ganesh; Anwar, Fahim; Mohamed, Biju

doi:10.25384/SAGE.11298278.v1

APPROVED_Xeomin_Prescribing_information_UKIE_combined_June_2019_v4.pdf (363.78 kB)

APPROVED_Xeomin_Prescribing_information_UKIE_combined_June_2019_v4 – Supplemental material for The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)

journal contribution

posted on 2019-11-29, 13:06 authored by Francesca Morgante, Ganesh Bavikatte, Fahim Anwar, Biju Mohamed

Supplemental material, APPROVED_Xeomin_Prescribing_information_UKIE_combined_June_2019_v4 for The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®) by Francesca Morgante, Ganesh Bavikatte, Fahim Anwar and Biju Mohamed in Therapeutic Advances in Neurological Disorders